Lantheus Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Lantheus stock.
View analyst ratings for Lantheus or view top-rated stocks.

Wall Street analysts have given Lantheus a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Lantheus wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Lantheus is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Lantheus.

Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its earnings results on Thursday, February, 25th. The medical equipment provider reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.04. The medical equipment provider earned $94.15 million during the quarter, compared to analysts' expectations of $94.40 million. Lantheus had a trailing twelve-month return on equity of 11.05% and a net margin of 0.12%.
View Lantheus' earnings history.

Lantheus' stock was trading at $13.62 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, LNTH shares have increased by 59.3% and is now trading at $21.70.
View which stocks have been most impacted by COVID-19.

Lantheus issued an update on its FY21 earnings guidance on Thursday, February, 25th. The company provided EPS guidance of $0.34-0.39 for the period, compared to the Thomson Reuters consensus estimate of $0.42. The company issued revenue guidance of $385-400 million, compared to the consensus revenue estimate of $408.33 million.

4 equities research analysts have issued twelve-month target prices for Lantheus' shares. Their forecasts range from $17.00 to $29.00. On average, they expect Lantheus' share price to reach $23.67 in the next twelve months. This suggests a possible upside of 9.1% from the stock's current price.
View analysts' price targets for Lantheus or view top-rated stocks among Wall Street analysts.

4 employees have rated Lantheus CEO Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among Lantheus' employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Lantheus include Quidel (QDEL), Neogen (NEOG), Intellia Therapeutics (NTLA), Riot Blockchain (RIOT), Myriad Genetics (MYGN), Heska (HSKA), Meridian Bioscience (VIVO), Celldex Therapeutics (CLDX), Aspira Women's Health (AWH), OncoCyte (OCX), Quotient (QTNT), Nymox Pharmaceutical (NYMX), VolitionRx (VNRX), Trinity Biotech (TRIB) and ImmuCell (ICCC).
View all of LNTH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Exelixis (EXEL), Gerdau (GGB), Pieris Pharmaceuticals (PIRS) and Abeona Therapeutics (ABEO).

(LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Lantheus' stock is owned by a number of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.07%). Company insiders that own Lantheus stock include Brian A Markison, Cesare Orlandi, Derace L Schaffer, Heinz Christoph Maeusli, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall, Sam R Leno and Tudor Brown.
View institutional ownership trends for Lantheus.

LNTH stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Lantheus company stock in the last year include John J Bolla, Mary Anne Heino, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall, and Sam R Leno.
View insider buying and selling activity for Lantheus or view top insider-selling stocks.

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LNTH stock can currently be purchased for approximately $21.70.

Lantheus has a market capitalization of $1.45 billion and generates $347.34 million in revenue each year. The medical equipment provider earns $31.67 million in net income (profit) each year or $1.17 on an earnings per share basis.

Lantheus employs 595 workers across the globe.

The official website for Lantheus is www.lantheus.com.

Lantheus is headquartered at 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862.

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]